glycyl-aspartyl-aspartyl-aspartyl-aspartyl-lysine-2-naphthylamide: synthetic substrate linked via amide bond to fluorophore 2-naphthylamine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 172458 |
| SCHEMBL ID | 413179 |
| MeSH ID | M0080872 |
| Synonym |
|---|
| gly-(asp)(4)-lys-2-na |
| 70023-02-8 |
| gly-asp-asp-asp-asp-lys-2-naphthylamide |
| glycyl-aspartyl-aspartyl-aspartyl-aspartyl-lysine-2-naphthylamide |
| gly-(l-asp)(4)-l-lys-2-naphthylamide |
| l-lysinamide, glycyl-l-alpha-aspartyl-l-alpha-aspartyl-l-alpha-aspartyl-l-alpha-aspartyl-n-2-naphthalenyl- |
| SCHEMBL413179 |
| 19-amino-3-[(2-amino-1-hydroxyethylidene)amino]-6,9,12-tris(carboxymethyl)-4,7,10,13-tetrahydroxy-15-{hydroxy[(naphthalen-2-yl)imino]methyl}-5,8,11,14-tetraazanonadeca-4,7,10,13-tetraen-1-oic acid |
| DTXSID60990271 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.34) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||